Aldeyra Therapeutics (ALDX) Misses Q3 EPS by 5c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Doximity downgraded by BofA on AI investment concerns, margin pressure
• DA Davidson flags Duolingo DAU momentum stalling, keeps Neutral at $120